Olink Acquires IP from In Situ RCP | GenomeWeb

NEW YORK (GenomeWeb News) – Olink Bioscience said today that it has acquired a family of patents from the Danish firm In Situ RCP that it plans to use in its nucleic acid amplification and protein analysis applications.

The Uppsala, Sweden-based company said the three patents are related to target primed rolling circle amplification and amplifying circular molecules.

Olink's product line is based on its proximity ligation assay technology, which uses dual recognition of analytes and a DNA amplification reporter system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.